Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: Utility for detection of diverse HIV-1 subtypes
Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: Utility for detection of diverse HIV-1 subtypes
复制标题
DOI：
10.1097/01.qai.0000242465.50947.5f
复制
发表时间：
2006-11-01
影响因子：
3.6
通讯作者：
Golding, Hana
中科院分区：
文献类型：
--
作者：
Khurana, Surender;Needham, James;Golding, Hana
由于全球正在测试越来越多的HIV候选疫苗，因此区分疫苗诱导的抗体和病毒诱导的抗体至关重要。目前测试的大多数疫苗含有多种病毒成分。因此，许多疫苗接种者在FDA许可的HIV scrodetection测试中给出阳性结果。我们已经确定了Env-gp 41和Gag-p6中的保守序列，这些序列在感染后很快被识别，但不包括在大多数HIV候选疫苗中。建立了一种新的HIV血清学检测方法HIV-SELECTEST，用于区分疫苗诱导的抗体和由于真正的HIV感染引起的血清转换。重要的是要使这种检测方法具有全球相关性，因为世界各地进行的许多临床试验中，大多数HIV感染是由于非B亚型HIV-1。因此，目前的研究检查了全球超过3000例不同HIV亚型感染者的血浆样本的反应性。HIV-SELECTEST的特异性和敏感性均大于99%。检测到进化枝A、B、C、D、E、F、G、J和CRF的近期和已建立的感染。其他疫苗接种或临床试验中心流行性感染引起的抗体在本试验中无反应。因此，HIV-SELECTEST可能成为全球HIV疫苗试验、血库和人群筛查的重要鉴别诊断工具。
Because increasing numbers of HIV vaccine candidates are being tested globally, it is essential to differentiate vaccine- from virus-induced antibodies. Most of the currently tested vaccines contain multiple viral components. As a result, many vaccine recipients give positive results in FDA-licensed HIV scrodetection tests. We have identified conserved sequences in Env-gp41 and Gag-p6, which are recognized soon after infection but are not included in most HIV vaccine candidates. A new HIV serodetection assay, the HIV-SELECTEST, was established that distinguishes between vaccine-induced antibodies and seroconversion due to true HIV infections. It is important to make this assay globally relevant, because many clinical trials are conducted around the world where most HIV infections are due to non-B subtype HIV-1. Therefore, the current study examined the reactivity of plasma samples from > 3000 infections with diverse HIV subtypes worldwide. The HIV-SELECTEST performed at > 99% specificity and sensitivity. Both recent and established infections with clades A, B, C, D, E, F, G, J, and CRFs were detected. Antibodies elicited by other vaccinations or infections endemic to the clinical trial sites did not react in this assay. Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide.